Meridian Bioscience acquired the business of GenePOC from Debiopharm for up to $120m.

Meridian Bioscience, a provider of diagnostic testing solutions and life science raw materials, acquired the business of GenePOC, a Quebec, Canada-based provider of molecular diagnostic instruments and assays, from Debiopharm for up to $120m. Jack Kenny, Chief Executive Officer, commented: “This is a critical element of our strategy to re-position our Diagnostics business for sustainable long-term growth. GenePOC’s revogeneTM platform is an excellent fit for our customers and strategy to offer gastrointestinal-focused and other targeted diagnostic solutions to meet the diverse needs of today’s more complex health care system. We welcome the GenePOC team to the Meridian family and look forward to leveraging Meridian’s strong and established commercial infrastructure to offer revogeneTM and its menu of assays to our current and new customers.”